Omeros (OMER) Receivables - Net (2010 - 2026)
Omeros (OMER) posted Receivables - Net of $12.0 million for Q1 2026, up 10.21% sequentially from $10.9 million in Q4 2025, and up 70.04% YoY from $7.1 million in Q1 2025.
Omeros (OMER) Receivables - Net (2010 - 2026) Analysis & Trends
Omeros has reported Receivables - Net for 17 years, with the latest figure at $12.0 million in Q1 2026.
- Quarterly Receivables - Net rose 70.04% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 70.04% YoY) and the FY2025 annual result came in at $10.9 million, up 41.06% from the prior year.
- Receivables - Net improved to $12.0 million in Q1 2026 per OMER's latest filing, from $10.9 million in the prior quarter.
- Over five years, Receivables - Net peaked at $213.2 million in Q4 2022 and troughed at $6.3 million in Q2 2025.
- A 5-year average of $21.6 million and a median of $8.1 million in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 458.83% in 2022, then plunged 96.2% in 2023.
- Over 5 years, Receivables - Net stood at $213.2 million in 2022, then slumped by 96.2% to $8.1 million in 2023, then declined by 4.41% to $7.7 million in 2024, then soared by 41.06% to $10.9 million in 2025, then climbed by 10.21% to $12.0 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $12.0 million, $10.9 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.30 Mn |
| Jun 30, 2026 | 21.30 Mn |
| Mar 31, 2026 | 12.03 Mn |
| Mar 31, 2026 | 12.03 Mn |
| Dec 31, 2025 | 10.92 Mn |
| Dec 31, 2025 | 10.92 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | 6.28 Mn |
| Jun 30, 2025 | 6.28 Mn |
| Mar 31, 2025 | 7.08 Mn |
| Mar 31, 2025 | 7.08 Mn |
| Dec 31, 2024 | 7.74 Mn |
| Dec 31, 2024 | 7.74 Mn |
| Sep 30, 2024 | 6.39 Mn |
| Sep 30, 2024 | 6.39 Mn |
| Jun 30, 2024 | 8.08 Mn |
| Jun 30, 2024 | 8.08 Mn |
| Mar 31, 2024 | 7.64 Mn |
| Mar 31, 2024 | 7.64 Mn |